Logo

Numab Entered into a Development and License Agreement with Ono to Develop Immuno-Oncology Therapies for the Treatment of Cancer

Share this

Numab Entered into a Development and License Agreement with Ono to Develop Immuno-Oncology Therapies for the Treatment of Cancer

Shots:

  • Numab to receive ~$279.13M in research funding, up front and milestone along with royalties on future sales. Under the terms of the license agreement, Ono gets the intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target
  • The collaboration will combine Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise to advance the immuno-oncology pipeline for cancer patients
  • In Mar 2020, Numab has expanded its collaboration with Ono to discover and develop a multispecific antibody drug candidate for the treatment of multiple cancers

Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions